Catheter News and Research

RSS

In medicine, a catheter is a tube that can be inserted into a body cavity, duct, or vessel. Catheters . In most uses, a catheter is a thin, flexible tube ("soft" catheter), though in some uses, it is a larger, solid ("hard") catheter. A catheter left inside the body, either temporarily or permanently, may be referred to as an indwelling catheter. A permanently inserted catheter may be referred to as a permcath.

Codman Neuro develops new MRI-resistant programmable valve for treatment of hydrocephalus

Codman Neuro* has developed a new MRI-resistant programmable valve with eight different pressure settings, including a ‘virtual off’ setting, for the treatment of hydrocephalus, a neurological condition that affects more than one million children and adults in the United States.

22 Sep 2015

CardioDx announces national agreement with Quest Diagnostics to expand access to Corus CAD blood test

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics DGX, +1.23% the world's leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD).

From Quest Diagnostics 18 Sep 2015

Coloplast announces launch of most compact catheter for men in the U.S.

Coloplast announced the U.S. launch of SpeediCath Compact Male, the most compact catheter for men, designed so users can do more. The new product is less than half the size of a standard male catheter and may be stored, carried, used and disposed of more discreetly.

15 Sep 2015

Thoratec begins SHIELD II U.S. clinical trial to examine use of HeartMate PHP in patients undergoing high-risk PCI

Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun enrollment in the SHIELD II U.S. clinical trial examining the HeartMate PHP in patients undergoing a high-risk PCI (percutaneous coronary intervention) procedure.

4 Sep 2015

LEADLESS II study confirms positive benefits of St. Jude Medical’s Nanostim leadless pacemaker

St. Jude Medical, Inc., a global medical device company, today announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim™ leadless pacemaker for patients in need of a single-chamber ventricular pacemaker.

3 Sep 2015

First-line catheter ablation treatment superior to drug therapy for suppressing AF

First-line treatment with catheter ablation is superior to drug therapy for reducing atrial fibrillation, according to five year results from the MANTRA-PAF trial presented for the first time at ESC Congress today.

2 Sep 2015

AccuTec Blades acquires EPC’s Industrial Blades division

AccuTec Blades, Inc. today announced the acquisition of Edgewell Personal Care Company's (EPC) Industrial Blades division. EPC announced in May 2015 its intent to discontinue its industrial blade operations in Verona, Virginia and Obregon, Mexico. Today's announcement marks the completion of the sale process.

2 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

PRESTIGE study suggests novel target to prevent stent thrombosis

Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated thrombotic processes may be a realistic target for novel therapies to prevent stent thrombosis.

1 Sep 2015

Additional electrical isolation of left atrial appendage could improve freedom from AF

In patients with long-standing persistent atrial fibrillation (AF) despite standard treatment, additional electrical isolation of an area called the left atrial appendage (LAA) can improve freedom from AF without increasing complications, results of the BELIEF study show.

31 Aug 2015

Leadless cardiac pacemakers could overcome complications of conventional transvenous pacemakers

A leadless cardiac pacemaker showed "good safety and reliable function" during the initial six months of follow-up in the LEADLESS II study, investigators reported during a Hot Line presentation at the ESC congress 2015.

31 Aug 2015

University of Huddersfield researchers develop new device to improve quality of care for young cancer patients

A DEVICE, developed through a collaboration by a team at the University of Huddersfield and a local charity, is set to improve the quality of care for child cancer patients. Medical practitioners and a dedicated charity have signalled that they are highly impressed by the design for a special harness, that safely and comfortably, contains the tubing inserted into the chests of youngsters during treatment.

29 Aug 2015

Children's Hospital Los Angeles successfully implants Melody Transcatheter Pulmonary Valve in child actor

Cardiologists from Children's Hospital Los Angeles successfully implanted a Melody Transcatheter Pulmonary Valve in child actor Max Page, the boy who made headlines playing mini Darth Vader in a 2011 Super Bowl ad for Volkswagen.

28 Aug 2015

Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

According to a new market report published by Persistence Market Research titled "Global Market Study on Urinary Catheters: Intermittent Catheters Segment to Witness Highest Growth by 2021", the urinary catheters market is expected to be valued at US$1,377.5 Mn by the end of 2015. It is anticipated to expand at a CAGR of4.1% from 2015 to 2021, to reach US$1,755.0 Mn by 2021.

From B. Braun Melsungen AG 27 Aug 2015

Shire enters into agreement with Sanquin for CINRYZE

Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.

25 Aug 2015

Few U.S. hospitals comply with CDC infection prevention guidelines for arterial catheter insertions

According to a survey conducted by Rhode Island Hospital researchers, there is significant variability regarding how clinicians manage catheters placed in the arteries of patients in intensive care units. Some practices may increase risk of infection associated with these catheters. Fewer than half of those surveyed complied with current Centers for Disease Control and Prevention (CDC) infection prevention guidelines for arterial catheter insertions.

21 Aug 2015

Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Loyola University Medical Center is the first and only hospital in Illinois to offer a new, noninvasive technology to test for coronary artery disease.

21 Aug 2015

Loyola implants new percutaneous aortic heart valve that does not require open surgery

Loyola University Medical Center is the first center in Illinois to implant a new percutaneous aortic heart valve that does not require open heart surgery.

19 Aug 2015

Peripherally inserted central catheter use associated with lower-extremity DVT

Peripherally inserted central catheters (PICCs), a type of IV typically inserted in a vein in the arm, are frequently used by healthcare professionals to obtain long-term central venous access in hospitalized patients. While there are numerous benefits associated with PICCs, a potential complication is deep vein thrombosis (DVT), or blood clots, in upper limbs.

18 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015